Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
IJMS | Free Full-Text | The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
Treatment Algorithms for Crohn's Disease - FullText - Digestion 2020, Vol. 101, Suppl. 1 - Karger Publishers
Adalimumab | ECCO E-Guide
Tailoring anti-TNF therapy in IBD: drug levels and disease activity | Nature Reviews Gastroenterology & Hepatology
European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay | Science Translational Medicine
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy - Gastroenterology
PDF) P553 Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week
ECCO-EFCCA Patient Guidelines on Crohn's Disease (CD)
Frontiers | Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study - The Lancet Gastroenterology & Hepatology
PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial - The Lancet Gastroenterology & Hepatology
Adalimumab | ECCO E-Guide
Managing complex perianal disease after anti-TNF failure: Where to go next? - ScienceDirect
Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment | Frontline Gastroenterology
Full article: Management of Crohn's disease in poor responders to adalimumab
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease | NEJM
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
